We offer our registered users tailored information, free online courses and exclusive content.
Our platform has been renewed. All users registered at any of the old websites are kindly requested to reset their password. Why is this?
... or you lost your password?English
Meridiano Congress International
Event Manager: Giorgia Di Egidio
T +39 06 88595 245
F +39 06 88595 234
[email protected]
EXCEMED designed this programme in partnership with TOPEC Global.
New insights into MS pathogenesis and the discovery of new treatments have made daily clinical practice even more challenging for physicians involved in MS patient management. One of the significant issues in MS today is the timing of therapy and switching therapies from traditional first-line disease-modifying therapies to other first- or second-line therapies.
• Illustrate the immunological factors involved in the pathogenesis of multiple sclerosis and pathological findings
• Integrate clinical, radiological and neurophysiological data to corroborate MS diagnosis
• Incorporate information regarding prognostic factors and the risks/benefit profile of currently available and new drugs for multiple sclerosis into treatment decisions
08.15 EXCEMED Opening
G. Comi (Italy)
Chairs: H.P. Hartung (Germany) - Fred D. Lublin (USA)
08.30 L1: Genetics and genetic biomarkers
J. Hillert (Sweden)
09.00 L2: Lifestyle
A. Ascherio (USA)
09.30 L3: Immunopathogenesis: peripheral and central immune deregulation
H.P. Hartung (Germany)
10.00 Coffee break
10.30 L4: Pathology of damage: relapsing remitting and progressive MS
W. Brück (Germany)
11.00 L5: Remyelination: new insights from molecular and microstructural imaging
B. Bodini (France)
Chairs: G. Comi (Italy) - F.D. Lublin (USA)
11.30 CC1: Diagnosis and differential diagnosis
Speaker to be announced
12.00 CC2: MRI in diagnosis and monitoring of MS and MS mimickers
M.A. Rocca (Italy)
12.30 CC3: Neurophysiology and OCT in diagnosis and monitoring of MS and MSmimickers
L. Leocani (Italy)
13.00 Lunch
Chairs: H.P. Hartung (Germany) - G. Comi (Italy)
14.00 L6: Prognostic factors and treatment choice
F. Lublin (USA)
14.30 L7: Assessment of treatment response
X. Montalban (Spain)
15.00 L8: Efficacy and safety of treatments with pleiotropic and antiproliferative MoA
M.S. Freedman (Canada)
15.30 L9: Efficacy and safety of treatments with targeted cells lysis and antimigratory MoA
Speaker to be announced
16.00 Coffee break
16.30 L10: Novelties in progressive MS
A.J. Thompson (UK)
17.00 L11: New goals, new treatments, new monitoring needs
G. Comi (Italy)
17.30 Concluding remarks
End of the meeting
